BioLargo, Inc. (OTCQX:BLGO) has announced that subsidiary Clyra Medical Technologies is expanding the distribution of its FDA 510(k)-cleared ViaCLYR™ wound irrigation solution through an agreement with Spartan Medical Inc. The arrangement is intended to support resale to government healthcare facilities worldwide and adds to Clyra’s existing U.S. and international distribution channels.
#Spartan Medical agreement
The announced arrangement is described as an exclusive purchasing agreement under which Spartan Medical will resell ViaCLYR™ to government healthcare facilities. The product has also been added to the Defense Logistics Agency Electronic Catalog, known as ECAT.
The facilities identified as eligible include VA/DoD-operated or managed locations, Federal Bureau of Prisons facilities, Indian Health Service facilities and other federal agency healthcare facilities. Certain civilian hospitals operating under VA Community Care or VA-funded contracts are also included.
#Existing distribution arrangements
Clyra’s new government channel supplements U.S. commercial distribution through Advanced Solutions. The company also has an international distribution agreement with Al Hikma covering 18 countries.
The source does not provide financial terms for the Spartan Medical arrangement or the other distribution agreements.
#ViaCLYR product claims and clearance
ViaCLYR™ is described as being FDA 510(k)-cleared for cleansing, irrigating and debriding several types of wounds. These include first- and second-degree burns, Stage I-IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds and abrasions. The clearance also covers moistening and lubricating absorbent wound dressings.
Clyra reports that clinical tests showed ViaCLYR™ killed 99.9999% of 18 pathogens within one minute of application. The release also describes 72-hour antimicrobial management without reapplication and says the product does not require rinsing because it is non-cytotoxic. The source does not provide further details on the clinical-test methodology or results.
#Commercial outlook and stated risks
BioLargo CEO Dennis Calvert said the Spartan Medical channel supports Clyra’s commercial rollout and revenue growth as the subsidiary scales manufacturing ahead of the anticipated national launch of its surgical product next year. These expectations are forward-looking statements attributed to the company, and the release says actual results may differ materially.
The company identified risks related to regional economic conditions and purchasing decisions, competition in markets subject to rapid technological change, the management and delivery of new products and services, customer demand and reliance on distributors. BioLargo also said it assumes no obligation to update its forward-looking statements or information.
#Statements from Clyra and Spartan Medical
Clyra Medical CEO Steve Harrison said the company expected ViaCLYR™ to become the standard of care across the VA, Military and Government healthcare continuum. Spartan Medical President Vince Proffitt referred to the product as addressing a persistent challenge for facilities served by the company and said Clyra was offering parity pricing.
Those comments are statements from company representatives. The source provides no independent confirmation of the standard-of-care expectation, the product comparison or the pricing statement.
#Key Takeaways
- BioLargo announced an exclusive purchasing agreement involving subsidiary Clyra Medical and Spartan Medical for ViaCLYR™ resale.
- The channel covers government healthcare facilities worldwide and includes facilities listed on the Defense Logistics Agency Electronic Catalog.
- Advanced Solutions remains Clyra’s U.S. commercial distributor, while Al Hikma covers 18 countries internationally.
- ViaCLYR™ is FDA 510(k)-cleared for cleansing, irrigating and debriding a range of wounds.
- BioLargo’s commercial and revenue expectations remain subject to the risks and uncertainties described in its release.
Original source: Read original article